🔗 Share this article The Global Health Body Sounds Alert Over Acute Scarcity of Weight-Loss Jabs Under a tenth of individuals eligible to benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it issues its initial advice on the therapies. Considering over a billion individuals worldwide currently living with obesity, it is calling for broader and more equitable availability to this class of drugs. Per projections, over two billion will be living with obesity by 2030 without intervention. "The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key barriers to broad access to the jabs that can help people shift significant body mass, explains the body. Weight-Loss Drug Supply Crisis Even under the current best projected scenario, the supply of such drugs would only suffice for about 100 million people – under 10% of those who need them, as stated by the health organization. The guideline urges countries and companies to widen availability, through approaches such as patent sharing. The intellectual property rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Jabs Operate The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so individuals reduce food intake. Individuals usually begin shedding pounds within a few weeks of beginning the once-weekly jabs. Evidence points to patients may put most of the weight back on within a year of discontinuing the medication, because their normal food cravings resume. Being overweight or obese elevates your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies. Obesity affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.
Under a tenth of individuals eligible to benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it issues its initial advice on the therapies. Considering over a billion individuals worldwide currently living with obesity, it is calling for broader and more equitable availability to this class of drugs. Per projections, over two billion will be living with obesity by 2030 without intervention. "The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key barriers to broad access to the jabs that can help people shift significant body mass, explains the body. Weight-Loss Drug Supply Crisis Even under the current best projected scenario, the supply of such drugs would only suffice for about 100 million people – under 10% of those who need them, as stated by the health organization. The guideline urges countries and companies to widen availability, through approaches such as patent sharing. The intellectual property rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Jabs Operate The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so individuals reduce food intake. Individuals usually begin shedding pounds within a few weeks of beginning the once-weekly jabs. Evidence points to patients may put most of the weight back on within a year of discontinuing the medication, because their normal food cravings resume. Being overweight or obese elevates your chance for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies. Obesity affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.